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1. Introduction
Despite the advances in chemotherapy over the last
few decades, survival is still poor in patients with un-
resectable metastatic colorectal cancer. Modern chemo-
therapeutic regimens, including oxaliplatin or irinotecan,
with at least one biological agent have extended survival
to approximately 2 years. However, tumour response
and time of disease control declines signiﬁcantly after
ﬁrst-line treatment, with a progression-free survival
historically ranging between 2 and 4 months after
second-line therapy. 1 Our clinic was interested in
investigating whether selective internal radiation ther-
apy (SIRT) could play a role in improving the response
to second-line chemotherapy by changing the tumour
microenvironment − improving the vascular ﬂow and
debulking the tumour. There is already some provisional
evidence to suggest that SIRT has a favourable effect
on the tumour growth. Phase I/II studies have shown
that SIRT is associated with a signiﬁcant debulking of
the tumour, as observed by the high response rates
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(as measured by RECIST), especially in the ﬁrst-line
setting. 2−5
It was considered that SIRT may also allow patients
a chemotherapy holiday between ﬁrst- and second-line
treatment. Two key studies from Europe have demon-
strated the favourable effects of a treatment holiday in
improving tolerability with oxaliplatin in the ﬁrst-line
setting (OPTIMOX study) 6 and treatment response to
irinotecan in the second-line setting (FOLFIRI3 study), 7
without diminishing overall survival.
2. InSIRT
In 2011, the InSIRT study was initiated to investigate
whether SIRT administered after ﬁrst-line therapy
could prolong progression-free survival compared with
historical controls. Subjects with predominant hepatic
metastatic colorectal cancer with evidence of progressive
disease following ﬁrst-line therapy with FOLFOX ±
bevacizumab were eligible for inclusion. All patients
received SIRT using yttrium-90 radioactive microspheres
within 4 weeks of completing ﬁrst-line chemotherapy.
Second-line therapy was initiated 4−6 weeks after the
ﬁnal SIRT. The primary objective is to assess the
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Fig. 1 – Progression-free survival (PFS) after second-line
chemotherapy with SIRT compared with the historical
control.
proportion of patients with progression-free survival
(PFS) as assessed by RECIST criteria, 6 months after the
date of disease progression on ﬁrst-line therapy. To date,
8 patients have been treated and 9 subjects enrolled
(goal 34 subjects) (Fig. 1). One subject was withdrawn
due to progressive lung metastases. Five of nine patients
have exceeded the expected PFS of 2.5 months with
a historical control. 1 Mean time to progression at the
last assessment was 6.7 months (range 0.7–17.3 months)
from the date of progression on ﬁrst-line therapy. 8
There is also some early evidence that the break from
chemotherapy to deliver SIRT allows patients to recover
from ﬁrst-line therapy and better tolerate second-line
therapy.
3. Conclusions
In conclusion, SIRT administered between ﬁrst- and
second-line chemotherapy is currently being evaluated
as a new approach to improve the duration of
response to second-line therapy in selected patients
with liver predominant metastatic colorectal cancer. In
parallel, investigators will assess changes in blood ﬂow
characteristics in the tumour using contrast-enhanced
ultrasound, and changes in molecular genetics of the
tumour (from tissue samples).
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